Idiopathicthrombocytopenic purpura(ITP) is characterizedby al ow plateletc ount, which is ther esult of bothi ncreasedp lateletd estruction and insufficient plateletp roduction. Although the developmento fa utoantibodies against plateletg lycoproteins remains central in the pathophysiology of ITP, several abnormalitiesinvolving thecellular mechanisms of immune modulationhavebeen identified.Conventional treatments forITP aim at reducing plateletd estruction, eitherb yi mmunosuppression Keywords Thrombocytopenia, plateletimmunology, immunity or splenectomy.Two newthrombopoietic agents,AMG 531and eltrombopag, have been used in clinical trials to stimulate plateletp roduction in ITPp atientsn ot responsive to standard treatments. Thesen ew molecules bear no structural resemblance to thrombopoietin, but still bind and activatethe thrombopoietin receptor.This reviewwill focus on the pathophysiologyand treatment of ITPinadults,highlighting recent advances in both fields.
Introduction
Primary immune thrombocytopenia,c ommonlyr eferred to as idiopathicthrombocytopenic purpura (ITP), is an acquiredautoimmune disorder defined by isolatedthrombocytopenia and the exclusion of othercauses of thrombocytopenia (1) .
ITP can be classified based on patient age (adultorchildhood ITP), and duration of thrombocytopenia (acute or chronic).The clinicalfeatures of ITP in adults are differentfrom the clinical features seen in childhood. In children, ITP is usually an acute, self-limiting disease, oftenoccurring 2-3weeks after aviral infection or immunization. In contrast, ITP in adults typically has an insidious onset, with no preceding viralorotherillness, and has achronic course.
Using alower-threshold plateletcount of 50 ×10 9 /l, the annual incidenceo fI TP among adultsh as been reportedt ob e 1.6-3.2 cases per 100,000 per year (2, 3) . Themedian age at diagnosis is 56 years,w ith af emalep reponderance in those younger than 60 years and equal proportions between sexes amongolderpatients (2, 3) . Manycases of ITP in adults are diagnosedincidentallyafter aroutine complete blood cell count (4) .
Individuals with aplateletcount stably between100 and 150 × 10 9 /l for at least six months arenot likelytodevelop amore severe thrombocytopenia;itisnot clear whether theyhaveahigher risk thant he generalp opulation of developinga nother autoimmune disorder (4) .I na dults,t he symptoms and signs are highlyvariable and range fromthe completely asymptomatic patient to frank haemorrhagef rom anys ite,t he most serious of whichisintracranial (5) .
Design of prospective,controlled clinicaltrials has been particularlydifficult, sincepatients with the chronic diseaseare less than10% of all ITP patients (6) and present considerableclinical variability.A ccordingly,s everal issuesr egarding the optimal treatment of these patients have remained unresolved,and principles of management have beenm ainlyb ased on expert opinions (1, (7) (8) (9) (10) . Nevertheless, ongoing randomized trials with several newp harmacologic agents promise to rapidly change this scenario.
The aim of this article is to provide an updatedreviewofITP in adults,focusing on our current understanding of the mechanismso ft he thrombocytopenia and on the evolving therapeutic modalities for chronic refractoryITP.
Pathophysiology of ITP
Although thep recipitating etiology for the loss of tolerance in ITP remains elusive,major advances have beenachieved regarding our understandingo ft he pathogenetic mechanisms of the disease. The simplistic viewo fI TP as ad isorderd etermined solely by plateletautoantibodies and characterized by increased platelet destruction hasbeen challengedbyboth clinicaland experimental data.Amuchmore complexsituation hasbeen envisaged ( Fig. 1) ,inwhich impairedplateletproduction and Tcellmediatedp lateletd estruction playas ignificant role,a nd dysfunction in more than one step of the immune regulation occurs (11) .
Role of Bcells
Harrington'sseminalexperiment published in 1951 provided the first evidencethat plateletdestruction in ITP is caused by aplasma-derivedfactor (12) ,later identifiedasantiplatelet antibodies (13, 14) . The most commonlyi dentified antigenic targets of these autoantibodies areplateletglycoproteins (GP)IIb/IIIa and Ib/IX, with anumber of ITP patients having antibodies directed to multiple plateleta ntigens (15) .I ts hould be noted,h owever, thata utoantibodies aren ot detectablei nu pt o5 0% of ITP patients (15, 16) and that remission in ITP cano ccur despite the presence of platelet autoantibodies (17) . Antibodies against GP IIb/IIIashowclonalrestriction in light-chainuse (18) ,and antibodies derived fromp hage-displayl ibraries showh ighlyc onstrainedVHgene use (19, 20) . Sequencing of the antigen-com- The activated Th cell producescytokines(interleukin-2and interferon-γ) that promote B-cell differentiationand autoantibody production. Autoantibodiesopsonize platelets,whichare takenupand destroyedbymacrophagespredominantly in thespleen.Theyalso bind bone marrow megakaryocytes, thereby impairing megakaryocyte maturationand platelet production. An alternativepathwayofplateletdestructionisby autoreactivecytotoxicT cells, althoughthe relevance of this mechanism in vivo is not known.
Stasietal. Update on ITP Stasietal. Update on ITP bining regions of these antibodies suggests that theyo riginate from alimitednumber of B-cell clonesbyantigen-driven affinity selection and somatic mutation (20) .
Role of Tcells
Tcells also appear to be related to the pathogenic processinITP, as aseries of studieshavedemonstrated thatB-cell production of antiplateleta ntibodies requiresa ntigen-specific CD4+ T-cell help (21) . Platelet-reactive Tcells have beenfound in the blood of patients with this disorder,with the major target antigenbeing GP IIb/IIIa (22) . In these patients, Tcells stimulate the synthesis of antibodya fter exposure to fragments of GP IIb/IIIab ut not after exposure to native proteins (23) .The derivation of these cryptic epitopes in vivo and the reasonfor sustained T-cellactivation are unknown. It has beenh ypothesizedt hat cryptic epitopes, normallynot exposed in aself-antigen, maybecomeexposed and recognizedb ythe immune system under certaincircumstances,for example, an infection (24) . Ancillary evidence for the involvement of Tcells comes fromstudiesshowing that patients with chronic ITP oftenhaveincreased numbersofHLA-DR+ Tcells, increased numbers of soluble interleukin-2recep-tors ( 25) , an increased Th1/Th2 ratio, and expansion of oligoclonalT -cells (26, 27) . Finally, CD3+ Tcells from ITP patients were found to have an increased expression of genesinvolved in cell-mediatedcytotoxicity,and the presenceofcytotoxic Tcells againsta utologous platelets wass hown in patients with active ITP (28) .
Immunological tolerance failure
The emergence of antiplatelet autoantibodies and antiplatelet cytotoxic Tcells is aconsequence of aloss of the immunological tolerance for self antigens. Tc ells recognizing peptidesg enerated fromnativeGPIIb/IIIa by normal processing pathwaysare hypothesizedt ob ed eleted in the thymus (negative selection), sinceGPIIb/IIIa has been showntobeexpressed on the cell surface of the epithelialcells of the thymic stroma earlyinintrauterine life (29) .However,Filion et al.haveshown that autoreactive Tcells directed againstGPIIb/IIIa are present in the peripheral blood of all healthyi ndividuals (30) ,i mplying thatp eripheral tolerance mechanisms are crucial to prevent autoreactiveTcells from becoming activated. As amatteroffact,several abnormal findings have emerged fromthe investigation of immune regulation in ITP patients. Among these,CD4+CD25+regulatoryT cells are decreased in number and with impaired suppressive activity when compared to healthys ubjects (31) .Also, CD3+T lymphocytesfrom patients with activeITP present an alteredexpression of genesassociatedwith apoptosis and are significantly more resistant to dexamethasone-induced suppression compared to normallymphocytes (28, 32) .
As farasBcells are concerned,the expansion of autoreactive clones is suppressedinthe bone marrow. If some Bcells escape this suppression or deletion, peripheral mechanisms, most importantlyt he functional balance betweena ctivating and inhibitory Fc receptors (FcR), maya lso be launchedt om aintain tolerance (33) .
Ther ole of antigen-presenting cells (APCs) for the loss of tolerance in ITP remains unclear,but amodel has beenadvanced in whichA PCs are crucial in generating an umber of newo r cryptic epitopesfrom platelet glycoproteins (34) . In this model, APCs expressing these novelp eptides, alongw ith co-stimulatorym olecules, induce the activation of Tc ells thatr ecognize these additionalp lateleta ntigens. Thus, this acquiredr ecognition of newself-determinants, or epitope spreading,may playan important rolei nt he initiation and perpetuation of ITP.T -cell clones thatreact with cryptic epitopesmay escape the negative selection in the thymus when self-determinants are present at a sub-threshold concentration.
Role of cell-cell interactions
Intercellular communication is essential forboth the activation and effector phases of Tcells, Bcells and macrophages.Optimal T-cellactivation requires twosignals. Thefirst signal is basedon T-cellreceptor (TCR) recognition of complexes of peptide/major histocompatibility complex (MHC).The second signal is provided by interaction of CD28,CD2 and LFA-1 on Tcells with their costimulatoryl igandsB 7, LFA-3a nd ICAM-1, respectively, on antigen-presenting cells.The activatedThcellproduces cytokines thatpromoteB-cell differentiation and antibodyproduction.Ongoing interaction betweenTcells and Bcells through CD40-CD40L (CD154) is necessary to maintain activeplatelet autoimmunity (11) . Platelets themselves express CD154. Normally, surface levels of CD154 are low, butthese increase after platelet activation (35,3 6) . Increaseda mounts of CD154 and its messengerRNA were found in the platelets and megakaryocytes of patients with ITP,and were able to drivethe activation of autoreactiveBlymphocytes, suggesting apossible active roleofplatelets in the autoimmune process (37) . Finally, an enhanced expression of CD80 (B7-1) on platelets from patients with ITP was observed, implicating arole of B7/CD28 costimulation in the pathogenesis of this disorder (38) .
Mechanisms leading to the thrombocytopenia
Autoantibody-dependent phagocytosis is thought to be the primary mechanism of plateletd estruction in ITP (34) . Both invitro and clinical studieshaveshown that the spleenisthe primarysite of antibodyproduction (39, 40) and is also the dominant organfor the clearanceofIgG-coated platelets (41, 42) . In aminority of patients, hepatic clearance predominates. Human macrophages express several Fc receptors thatbind IgG specifically (43) . Functionally, there are twodifferent classes of Fc receptors:the activation and the inhibitoryreceptors, whichtransmit their signalsvia immunoreceptor tyrosine-based activation (ITAM)orinhibitorymotifs (ITIM),respectively. Clinical data, alongwith information gainedfrom animalmodels, suggest that the FcγRI, the high affinity receptor,does not playarelevant role in ITP (44, 45) . On the other hand,evidencehas accumulated to indicatet hat the low-affinity receptors FcγRIIAa nd FcγRIIIA areprimarily responsiblefor removalofopsonizedplatelets (46) . Engagement of FcγRIIAonthe surfaceofhuman macrophages by anti-GPIIb/IIIa-coated platelets triggers intracellularsignaling throughthe tyrosine kinase Syk, that leads to engulfment of the opsonized platelets.
The presenceofantibodies against GP Ib/IX has beenassociated with resistance to intravenous immunoglobulin (IVIG) therapyboth in amouse model (47) and in retrospective seriesofITP patients (48) . These findings suggest the possibilityofdirect cytotoxicity or complement fixation as am echanism of platelet destruction rather thana ntibody-dependent, Fc receptor-mediated phagocytosisbymacrophages.
Recently,in-vitro studies have produced evidencefor direct T cell-mediatedc ytotoxicity against platelets (28) .W hethert his effect occurs in vivo,its relativeimportanceindetermining plateletdestruction, and whether the same cytotoxic Tcells exerta rolea gainst bonem arrowm egacaryocytesh as notb een elucidated.
Studies by several groups of investigators( 41, 42, 49, 50) using indium-111 ( 111 In)-labeleda utologous platelets showed considerableh eterogeneity in platelett urnoveri nc hronic ITP. Although the plateletl ifespan is oftenm arkedlyd ecreased,i n some patients the lifespanisonlymildlyreduced; furthermore, plateletturnover(ameasureofplateletproduction) is frequently subnormal. Overall, approximately 40% of patients with ITP had areduced platelet turnover (41, 42) . In keeping with this finding, autoantibodies against plateletglycoproteins have beenshown to interferewith the maturation of megakaryocytes, resulting in reduced platelet production (51, 52) . In-vitro studies have shown thata ntibodies that target the GpIb-IX-Vc omplexm ay induce thrombocytopenia both by inhibiting megakaryopoiesis (52) , and by inhibiting proplateletformation (53) .
Current therapeutic options forpatients with ITP
There is no evidencebased on randomized trials to guidemanagement decisions, and fors ome patients the morbidityf rom side effects of therapymay exceed anyproblems caused by the ITP (5, 6) . Treatment of patients with ITP must take into account the age of the patient, the severity of the illness, and the anticipatednatural history. Adultpatients, particularlythose older than 60 years of age, have ahigherincidence of major or fatalbleeding thanc hildren (5) .H owever,s pecific therapym ay not be necessary unless the plateletcount is <20x10 9 /l or there is extensive bleeding.Infact,atthe present timetreatment for ITP is consideredappropriate for symptomatic patients and for those at risk of bleeding (1, (7) (8) (9) (10) .
Initial treatment
Once thedecision to treat apatient with ITP has been made,and provided the patient'ssituation is not life-threatening,corticosteroids arethe standard initial treatment (1) .The mechanism of action of corticosteroids in ITP is still obscure, although theyhave beenshown to impair the clearanceofantibody-coated platelets by mononuclear macrophages (54),decreaseautoantibody production (55),a nd improve the integrity of leaking capillaries (56) . Thecurrent practice is to initiate treatment with oralprednisolone or prednisone, 1to2mg/kg per day, givenassingle or dividedd oses. Approximately twot hirds of patients achieve a completeorpartialresponsewith corticosteroids,and most responses occur within the first week of treatment (7) . However, only10-15% of all adult patients with ITP whoreceive prednisone therapyh avead urabler emission (7) . Twol arge non-randomized studieshaveshown that ashortcourse of treatment with high-dose orald examethasone( 40 mg/dayf or 4c onsecutive days) waswelltoleratedand effective compared to standard-dose therapy (57, 58) . Despitethis success, the use of this regimen as first-line therapyhas notbeen validated.
IVIGs are generallyrecommendedfor patients with critical bleeding and forthose unresponsive to corticosteroids (1) . The preponderance of evidencec ontinues to supportt he original postulate that the beneficial effect of IVIG in ITP is atransient impairment of reticuloendothelialc learance function, also referred to as macrophage '' blockade''mechanism (59). Samuelsson et al.havedemonstrated thatIVIG requires thepresence of the inhibitorylow affinity IgG receptor FcγRIIBfor prevention of thrombocytopenia in am urine model of passive ITP (60) . They have also demonstrated thatsome monocytes from IVIGtreatedmicebegin to express the FcγRIIBatelevatedlevelswith-in fourhours of IVIG administration. This increase in FcγRIIB resultsi nachange in the ratioo fe xpression of the inhibitory FcγRIIBa sc ompared to stimulatoryF c γ RIII. Thew ay IVIG functionsvia FcγRIIB is still unclear.Genetic and biochemical studiesh avei dentified the SH2 domain-containing inositol 5-phosphatase (SHIP1) as ac ritical effector in FcγRIIB inhibitory signaling (61) .Whetherornot this pathway is involved in IVIG action,however,has notbeen established, and in amurine model of ITP the individual expression of SHIP1 (and two other potential signaling mediators, SHP-1 and Btk) wasn ot requiredfor IVIG action in amelioration of immune thrombocytopenia (62) .OtherimmunomodulatoryeffectsofIVIG include inhibition of complement binding to platelets, interference of immune complexesbindingtoplatelets, immune activity of antiidiotype antibodies, and impaired releaseo fp ro-inflammatory cytokines frommonocytes (59) .Several regimens for IVIG have beenused. In currentpractice the standard dose is 1g/kg perday for onetotwo days (7) .IVIG is effective in elevating the platelet count to morethan 50 ×10 9 /l in approximately 80% of patients. In more than half of responders, the plateletcount becomes normal (>100 ×1 0 9 /l) (63) . Plateletc ounts mayb egin to increase after oneday and usually reach peak levels within one week after treatment (64) . However, response is generallytransient, lasting no longer than3 -4 weeks,a fter whicht he plateletc ounts decrease to pretreatment levels. Thus, IVIG therapyisidealwhen a rapid increase in plateletc ount is desiredi np atients with lifethreatening bleeding and can also be combined with steroids and platelet transfusions in these situations (7) .
The plateletcount also canbesupported by anti-Dimmunoglobulin, whichi sa ctiveo nlyi nR h-positive patients and in the presplenectomys etting (65) . Anti-Db inds to the erythrocyte D-antigen. Immune-mediated clearance of the sensitized erythrocyteso ccupiest he Fc receptors in the reticuloendothelial system, minimizing removalo fa ntibody-coated platelets (59) . The response rate to intravenous anti-D at the dose of 50 µg/kg was70% in the largest series published to date (65) .The increase in plateletcount wasseen after 72 hours, and lastedmore than 21 days in 50% of the responders. At doses of 75 µg/kg, anti-D not onlyincreases the plateletcount more rapidly, and foralonger duration comparedwith the standard dose of 50 µg/kg, butplateletresponses within 24 hours occur in the majority of patients, faster thanthose that have beenreported with corticosteroids and as fast as thoser eported with IVIG (66) . Subcutaneous anti-D hasbeen triedinafew patients suffering from chronic ITP (67).
Stasietal. Update on ITP
None of thepatients treated with this alternateroute of administration developedhaemolysis or anyothersignificant reaction. In addition, subcutaneous deliveryofanti-D seemed to produce largelythe same beneficial effect observed with intravenous delivery.
The repeated use of either maintenance IVIG(68) or maintenance anti-D globulin (69) allows approximately 40% of adults with ITP to avoid splenectomyaltogether. Considering the substantiallyl ower costs and shorter infusion time (minutesc ompared with hours) of anti-D comparedtoIVIG, theformer should probablybepreferred for the long-termuse.Arandomized,controlled trial has tested the potential of anti-D to avoid or defer the needfor splenectomyinnewly diagnosedadults with ITP and a plateletcount <30,000/µl. There were no differences in the rates of spontaneous remission or the need forsplenectomybetween the anti-Dgroupand the routine care group (70) .However,splenectomywas performed prematurely, not according to protocol, in 11 of 14 patients. This mayhaveaffected the inability to show adifference between the twogroups with regard to rates of splenectomy.
IVIG and particularlya nti-D canc ausem ild alloimmune haemolysis, and IVIG mayalso causeheadache, nausea, and vomiting, symptoms thatmay causeconcern for the possible occurrence of intracranialhaemorrhage (71) .Some sucrose-containing products mayalso be associatedwith acuterenal failure (72) . Anti-D immunoglobulin canrarelycauseintravascularhaemolysis and disseminatedi ntravascularc oagulation (73) .A nti-D should not be used,orusedwith extremecare, in patients with a positive direct antiglobulin test and ahaemoglobin levelthat is less than 10 g/dl, due to the risk of increasing the severity of the anemia.
Emergencyt reatment is indicated fori nternal or profound mucocutaneous bleeding.H ospitalization is required, and general measures should be instituted to reducethe risk of bleeding, includingavoidanceofdrugs that inhibitplateletfunction, control of blood pressure,and other factors. Althoughnosystematic studies have evaluatedthe efficacyofdifferent regimens, there is general agreementthat appropriate interventions should include the following (1, 7, 74): -I VIG, (1 g/kg, repeated thefollowing dayifthe plateletcount remains <50x10 9 /l) -I ntravenous methylprednisolone, 1g/d for 3days -P latelettransfusions (either 10 Uevery 4-6 hours or 3U/h) Althoughpatients with ITP are assumed to have arapidplateletd estruction, transfusedp latelets mayp rovide temporary critical haemostatic support ( 75) . Platelet transfusions usually aregiven after IVIG and are ofteneffectiveincontrolling bleeding, irrespective of the increase in plateletc ounts. If critical bleeding continuesafter initialmanagement with platelettransfusions,I VIG, and methylprednisolone,i ntravenous recombinant human factor VIIa maybeeffective(76-80).
Second-linetreatment
Splenectomyi st raditionallyc onsideredt ob et he second-line treatment in adults with ITP in whom achieving asafe platelet count with initialp rednisonet herapyh as failed. Generallya ccepted criteriafor splenectomyinclude asevere thrombocytopenia (<10 x10 9 /l),ahigh risk of bleeding forplateletcounts less than 30 x10 9 /l, or the requirement of continuous glucocorticoid therapytomaintainsafe platelet counts(1).
Asystematic reviewof47caseseries with 2,623 patients indicates acomplete response (platelet count >150 ×10 9 /l) rate of 66%(range, 37%to100%) (81) .Of707 evaluablepatients with at leastf ivey ears of follow-up, 456 (64%) retained their response status. Most relapses occur during the first twoyears after splenectomy, bute vena fter thatasmall percentage of patients continuedt or elapse. No preoperativec haracteristic that has beenr eported predicted responset os plenectomyc onsistently. Yo unger age waslinked to agood response, butnospecific age could be defined (81) .
Splenic sequestration of 111
In-labeled platelets wasagood prognosticfactor in many studiesinwhich this scanning method wasapplied. In the large study by Najean et al., asplenic pattern of plateletd estruction hadap ositivep redictive value of 93%, whereas ahepatic or diffusepattern of plateletdestruction hada negative predictive value of 77% (82) . However, plateletsequestration studiesare difficult to performand areavailableinonlya fewm edical centers.F urthermore,t he specificity of the test is not high enough to recommend it routinelyfor patients in whom splenectomyhas been considered.
Occasionally, patients mayfailtorespond to splenectomybecauseofthe failuretoremoveanaccessoryspleen. In other patients, as mall, inactivea ccessorys pleenm ay grow or new splenic focimay develop from splenic cells shedatthe timeof surgery and causethe late onset of thrombocytopenia. In either case, the presenceofsplenic tissue canbediagnosedbyexamination of the blood smearfor Howell-Jollybodies that appear in the redcells of asplenicindividuals. Persistent splenic tissue can be confirmed by aradionuclide scan.
An alternativet oc onventional open splenectomyi sl aparoscopic splenectomy. Several studieshaveshown reducedblood loss with this procedure and morerapidrecovery time,and suggestedalower mortality rate compared with opensplenectomy (0.2% and 1.0%, respectively) (81) .
Splenectomizedpatients have asmall risk for overwhelming infections,with an estimatedmortality of 0.73 per 1,000 patientyears (83) .T he risk for serious postsplenectomyi nfection is greater in children younger than five years,w ho aret herefore treatedwith prophylactic penicillin after splenectomy. Although there are no data on theefficacyofvaccination, immunizations againstencapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae B,a nd Neisseria meningitides)a re generallya dvised at least twow eeks befores plenectomy ( 1) . The usefulness of postoperative antibiotic prophylaxis is amatterof controversy, and although it is not the standard of care in the UnitedS tates, life-longp rophylactic antibioticsa re recommendedinUKguidelines (84) .
Tr eatment of patients in whomsplenectomyfails
Patients can be definedashaving chronic refractory ITP if splenectomyfails and the patients requireadditional therapy. About 30% of adultpatients with ITP maybelongtothis category (85) . The goals of therapyfor refractoryITP areclearlydifferent from Stasietal. Update on ITP thosefor patients at initial presentation because the chance of inducing adurable, complete, and unmaintainedremission is much lower. The objective of treatment for patients with refractoryITP is to achieve stable adequateplateletcounts (>20 to 30 x10 9 /l) while minimizing the adverseside effectsofmedication (7) .
Patients whohavearelapseare generallytreated again with corticosteroids,which areonlytransientlyeffective, have lowresponse rates and substantial toxicity with dailyu se.I nr ecent years several studieshavereported the use of anti-CD20mono-clonalantibody rituximab in patients with chronic ITP,both prior to and after splenectomy. Rituximab eliminatesnormal Bcells, includingt hose producing antiplateleta ntibodies (86) .T his B cell depletion is transient (lasting 6to12months, in most cases) and has fewside effectsortoxicities (86) . Arecent reportindicates that rituximab exerts significant effectsoncellularimmunity as well (27) . Pretreatment abnormalitiesofTcells in ITP patients were reverted in responders at three and six months after anti-CD20therapy, whereas theyremained unchanged in non-responders.Furthermore,astrong association wasfound between failuretorituximabtherapyand oligoclonal expansion of Tcells (27) . An attractive hypothesis to explain this finding is that rituximab mayb es ufficiently immunomodulatoryt op roduce a clinical remission at an earlystage of ITP,when expansion of pathogenic Tcells hasnot reached a"critical"level and is still dependent uponB-cell costimulation. In contrast, when T-lymphocyte clones are moreexpandedtheycontinue to drive antibody production irrespective of the cytokinemicroenvironment produced by Bcells. Theresults of alarge clinical trialwith rituximabare consistent with suchaspeculation (87) .Inthat study patients with ashortdiseasehistory, in whom presumably T-cellexpansion wasnot yetcritical,were muchmore likelytorespond to treatment thanthose with an ITP duration of manyyears.Therefore, non-responsiveness to anti-CD20 therapyinITP mayberelatedtoaninability to modify the oligoclonal natureofthe T-cell subsets.
Asystematic analysis of the published literaturesuggests that rituximab produces an initial response in approximately 60% (range,2 5-75%) of cases, with no significant difference between splenectomized and non-splenectomized patients (88) . Them edian responsed uration is 10.5 months (range,2 -48 months), with a15-20% rate of long-termcomplete responses.A recent French study indicates thatthe use of rituximab allows to defer splenectomyfor at least one year in 40% of patients with chronic ITP (89) .
Several other drugshavebeen reportedtohavesome activity (although not consistently) in refractoryITP.These include the attenuated androgen danazol,dapsone, azathioprine, cyclophosphamide, vincaa lkaloids,r ecombinanti nterferon-γ2B,c yclosporin A, and mycophenolatemofetil,alone or in combinations (7) . Responseswith these agents do not usually exceed 30-35% and,ifseen, theymay onlybeapparent after several weeks.More experimental approaches include campath-1H,liposomaldoxorubicin, protein Ai mmunoadsorption columns,a nd peripheral blood stem cell transplantation (7) .The toxicities associated with these agents should be carefullye valuatedw hen further treatment is required.
Management of the thrombocytopeniacomplicating other immune disorders
Thrombocytopenia can complicateo therd isorders of immune dysregulation, includinga utoimmune haemolysis (the combination is called Evans' syndrome),systemic lupus erythematosus (SLE), the antiphospholipid syndrome, and common variable immunodeficiency. The approach to treatment should parallel considerationsgiven forthe treatment of primaryITP.However,f or some of these conditions (e.g. Evans' syndrome),t he thrombocytopenia maybelessresponsivetofirst-line treatment (corticosteroids and splenectomy).I nt he case of thrombocytopenia complicating SLE, danazol and hydroxychloroquine, when used with glucocorticoids,resultedinsustained remission rates of 50% and 64% of cases, respectively (90) . Ther ole of splenectomyinSLE remains controversial, and it should be used onlywhen the thrombocytopenia is severe and persistent and is the predominant reasonfor treatment and when the SLE is otherwisewellcontrolled (90) .Thrombocytopenia is acommon finding in patients with the antiphospholipid syndrome, and requires treatment strategies similar to those used for patients with ITP (91) .Anissue of clinical importanceine valuating thrombocytopenia associatedw ith the antiphospholipid syndrome is the risk for future development of thrombosis, sincem oderate thrombocytopenia does not prevent thrombosis in these patients (92) .
Immune thrombocytopenia also occurs with increased frequencyi np atients with common variable immunodeficiency (93) .Common variable immunodeficiencyshould be suspected in patients with even mild recurrent infections and allergies. Splenectomyand immunosuppressive agents should be avoided to the extent possible (94) .
Anovel therapeuticapproach: thrombopoietic agents
Current treatments for ITP aim at suppressing the production of autoantibodiesand/or inhibiting macrophage-mediateddestruction of opsonized platelets. As discussedabove,however,several patients have impaired platelet production rather thatincreased plateletd estruction. Additionally,I TP patientsh aven ormal or slightlyelevatedthrombopoietin (TPO) levels whether measured in plasma or serum, butthe levels are always lowerthan the concentrations found in thrombocytopenias resulting from megakaryocytic hypoplasia (95) (96) (97) .T his finding probablyr esults from active TPOuptakeand destruction by the expandedmegakaryocyte mass in ITP.Onthese grounds, growth factor stimulation of megakaryopoiesis might be expected to increase the plateletcount in patients with ITP.
First-generation thrombopoietins usedi nc linical trials included recombinant humanTPO (rhTPO), and anon-glycosylated, truncated form of TPO coupledtopolyethylene glycol. The recombinantprotein,called"megakaryocyte growth and differentiation factor"(MGDF), hadimportant differences compared to native TPOt hat probablye xplain its immunogenic potential (98) .Clinical trials were discontinuedafter the development of TPO autoantibodiesw as observed in healthyv olunteers ( 99) , and did not yield aclinically approvedtherapeutic thrombopoietin. Recently, however, intense clinical trialactivity hasresumed with second-generation thrombopoietic growth factors. These newmolecules bearnostructural resemblance to TPO,but still bind and activate the TPO receptor.Studieshavebeen completed fortwo TPOmimetics, AMG531 and eltrombopag.
AMG 531 is arecombinantprotein definedasa"peptibody" (Fig. 2) . It is made of twodisulphide-bonded immunoglobulin Fc fragmentseach of whichiscovalently bound at residue 228 with twoi denticalp eptide sequences linked viap olyglycine (100) . The carrierFccomponent of the molecule binds to the FcRn salvage receptor and undergoes endothelial recirculation, resulting in asubstantiallylonger half-life than the peptide alone.Results of phase 1/2 trials were publishedr ecently,d emonstrating that AMG531 givena saw eeklys ubcutaneous injection for 1-6 weeks leads to doubling of plateletc ounts and an increase to more than 50 x10 9 /l in approximately 75% of patients with minimal side effects (101, 102) .
Patients from the AMG531 phase 1-3 studies have beenenrolled in an open-labelstudy of long-termadministration of the drug. The plannedinterim analysis included36patients (safety subset), 29 of whom treatedfor longer than 48 weeks,whose previous study wasaphase II trial (103) .The analysis indicates that theyhad astablemean platelet count of greater than100 x10 9 /l, were on as tablew eeklyd ose, and half were able to stop other concomitant immunosuppressive drugs. The most frequentlyreported complication of therapyw as mild headache; in twop atients there wasamild-to-moderate increase in bonem arrow reticulin butwithoutcollagen fibrosis and with normal cytogenetic findings (101) .Results of arandomized,placebo-controlled phase III studyofsix monthsoftreatment with AMG531 in splenectomizeda nd non-splenectomizedI TP patientsh aven ot yet beenreported. Thepotential of AMG 531 as asplenectomy-sparing agentisbeing investigated in an ongoing phase IIIb trial, in whichthe thrombopoietic agent is comparedtomedical standard of care fornon-splenectomizedsubjects with ITP (seehttp://clini caltrials.gov/ct/show/NCT00415532 for details). Thetreatment duration is 52 weeks,and is followedbyasix-month safety follow-up study.
Eltrombopag (formerlyS B497115)i sas mall, orally available,hydrazone organic compound (Fig. 3) . This molecule was identifiedf rom high-throughput screening of small-molecule compoundc ollections, utilizing haematopoetic cell lines cotransfectedwith the humanTPO receptor,aluciferase gene,and several requisite signal-transduction responsive elements (104) . In arandomized,double-blind,placebo-controlledphase 2trial, subjects were givendaily oraltreatment with placebo or escalating doses of eltrombopag( 105). Platelet responses were observedin70% of patients at the 50 mg dose, and in 81% at the 75 mg dose. Furthermore,apreliminary analysis in 36 patients suggestedatrend toward fewerbleeding eventsontherapyinthose receiving the 50 mg and 75 mg doses.N os ignificant adverse eventsw ere seen. As ubsequent randomized,d ouble-blind, placebo-controlledp hase IIIt rial enrolled1 14 adults with chronic ITP and baseline plateletc ounts of <30x1 0 9 /l (106). These patients were randomized to eitherplacebo (38patients) or eltrombopag50mg(76 patients) once dailyfor six weeks.The eltrombopagdose could be increased to 75 mg in patients not responding after an initial threew eeks of treatment. All patients hadreceivedprior ITP treatment and 52%had received ≥3prior therapies. At the end of the trial, 16% of placebo patients and 59%o fe ltrombopagp atients achieved the primary endpoint (platelet count ≥50 x1 0 9 /l).I mportantly, there wasasignificantly lowerincidence of bleeding eventsduring treatment with eltrombopagcompared to placebo (p=0.029) with clinicallysignificant bleeding (WHO grades 2-4) observed in fewereltrombopag patients (16%) thanp lacebo patients (36%). Them ost common adverse event observed in this studywas headache, but this could not be attributedt ot he study medicine.S everal eltrombopagt rials investigating the short-a nd long-termt reatment of chronic ITP are currently open and enrolling (see http://clinicaltrials.gov/). 
Stasietal. Update on ITP
There areotherthrombopoietic agents in development, such as AKR-501 (107), whicha ppearp romising in normalv olunteers. Ongoing phase IIIclinical trials will reveal the potentialof these agents in the management of ITP prior to splenectomyand for long-termmaintenance therapy, as well as their relativebenefitcompared to placebo or standard of care treatment.
Conclusions
Despite some fundamental tenetsofthe pathophysiologyofITP have beenknown for half acentury, important discoveries at the molecular levelhavebeen relativelyrecent.
Conceptsabout the mechanisms of the thrombocytopenia in ITP have shiftedfrom the traditionalviewofincreased platelet destruction mediatedb ya ntibodies, to am uch more complex situation where impaired platelet production and Tcell-mediated plateletdestruction have emerged as playing asignificant role. At the same time,n ew therapeutic approaches,s uch as rituximab, have beenevaluatedinadult patients with ITP.These findings have beenp articularlyi mportant for thosep atients who would prefertopostpone or avoid splenectomy. Thrombopoietic agents appeartobeveryeffectiveinahigh percentage of even refractorypatients with ITP,verytolerable, and safe. Theyappear to be amajor breakthrough in the treatment of patients with ITP.
